Agreement - March 7, 2025
Kancera signs letter of intent agreement with Recardio
The company has signed a letter of intent agreement with the private US biotech company, Recardio with the objective of combining both companies’ assets and forming a late clinical-stage multi-product cardiovascular-focused specialty care company.
MedTech Business - March 6, 2025
Bactiguard announces updated strategic and financial targets
Bactiguard has conducted an analysis of the market potential and partnership opportunities for its infection prevention technology.
Biotech Business - March 5, 2025
Fuse Vectors secures USD 5.2 million
Fuse Vectors announces USD 5.2 million in pre-seed financing led by HCVC.
Biotech Business - March 5, 2025
Neogap awarded grant to advance cancer immunotherapy
Neogap Therapeutics has been awarded a USD 125,000 ScaleReady G-Rex Grant to optimize the development and manufacturing of its personalized cancer immunotherapy, pTTL.
Business article - March 5, 2025
Zelluna announces the successful completion of a business combination
All conditions for completion of the business combination have been met, including, confirmation by Euronext Oslo Børs of the continued listing, approval of the prospectus and regulatory clearances, the new company states.
Intellectual Property - March 5, 2025
SynAct Pharma granted US patent
The United States Patent and Trademark Office (USPTO) has issued US patent 12,239,631 with claims covering the crystal form of resomelagon (AP1189) currently undergoing development in clinical phase 2b.
